Norway, Aug. 5 -- Lifecare ASA (LIFE), a MedTech company developing next-generation Continuous Glucose Monitoring (CGM) technology for diabetes management, is pleased to announce that it has received approval from the Regional Committee for Medical and Health Research Ethics (REK) in Norway for its planned first-in-human trial of the implantable GCM sensor.This marks a significant milestone, bringing Lifecare one step closer to initiating regulatory testing of its wireless glucose sensor for human use. The approved trial is designed to assess the safety, tolerability, and glucose-sensing accuracy of the implant in individuals with type 1 diabetes. The REK approval is conditional upon minor documentation updates and does not represent the fi...